{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T22:19:52Z","timestamp":1772749192864,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.clinthera.2011.07.011","type":"journal-article","created":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T21:27:38Z","timestamp":1312666058000},"page":"1023-1042","source":"Crossref","is-referenced-by-count":12,"title":["Pitavastatin Calcium: Clinical Review of a New Antihyperlipidemic Medication"],"prefix":"10.1016","volume":"33","author":[{"given":"Laurie L.","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.07.011_bib1","article-title":"Top 200 drugs of 2008","author":"Lamb","year":"2009","journal-title":"Pharmacy Times"},{"key":"10.1016\/j.clinthera.2011.07.011_bib3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2011.07.011_bib4","series-title":"Livalo (pitavastatin) [product information]","year":"2009"},{"key":"10.1016\/j.clinthera.2011.07.011_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib6","first-page":"904","article-title":"Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase","volume":"47","author":"Aoki","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2011.07.011_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5551\/jat1994.7.138","article-title":"Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells","volume":"7","author":"Morikawa","year":"2000","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2011.07.011_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1253\/circj.68.1061","article-title":"Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells","volume":"68","author":"Fan","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2011.07.011_bib9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbrc.2004.09.122","article-title":"Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell","volume":"324","author":"Maejima","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2011.07.011_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5551\/jat.12.163","article-title":"Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes","volume":"12","author":"Saiki","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2011.07.011_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2133\/dmpk.14.79","article-title":"Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans","volume":"14","author":"Fujino","year":"1999","journal-title":"Drug Metab Pharmacokinetics"},{"key":"10.1016\/j.clinthera.2011.07.011_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2133\/dmpk.13.484","article-title":"Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats","volume":"13","author":"Kimata","year":"1998","journal-title":"Drug Metab Pharmacokinetics"},{"key":"10.1016\/j.clinthera.2011.07.011_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2133\/dmpk.13.499","article-title":"Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats","volume":"13","author":"Fujino","year":"1998","journal-title":"Drug Metab Pharmacokinetics"},{"key":"10.1016\/j.clinthera.2011.07.011_bib14","first-page":"415","article-title":"Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans","volume":"14","author":"Fujino","year":"1999","journal-title":"Xenobio Metabol Dispos"},{"key":"10.1016\/j.clinthera.2011.07.011_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0378-4347(98)00523-4","article-title":"Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection","volume":"724","author":"Kojima","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.clinthera.2011.07.011_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1248\/bpb.22.142","article-title":"Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile","volume":"22","author":"Kojima","year":"1999","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clinthera.2011.07.011_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2133\/dmpk.14.415","article-title":"Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human","volume":"14","author":"Fujino","year":"1999","journal-title":"Drug Metab Pharmacokinetics"},{"key":"10.1016\/j.clinthera.2011.07.011_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/DMDI.2004.20.1-2.25","article-title":"Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities","volume":"20","author":"Fujino","year":"2004","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.clinthera.2011.07.011_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2133\/dmpk.16.497","article-title":"Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs","volume":"16","author":"Kojima","year":"2001","journal-title":"Drug Metab Pharmacokinetics"},{"key":"10.1016\/j.clinthera.2011.07.011_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/00498250400015319","article-title":"Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors","volume":"34","author":"Fujino","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2011.07.011_bib21","first-page":"382","article-title":"Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase","volume":"54","author":"Fujino","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2011.07.011_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2125.2004.02251.x","article-title":"Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis","volume":"59","author":"Hui","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2011.07.011_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2005.02462.x","article-title":"Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin","volume":"60","author":"Ando","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/0091270010379811","article-title":"Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers","author":"Inagaki","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib27","first-page":"251","article-title":"Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia","volume":"52","author":"Saito","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2011.07.011_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1345\/aph.1M522","article-title":"Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia","volume":"44","author":"Sansanayudh","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.07.011_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2217\/clp.09.20","article-title":"Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia","volume":"4","author":"Budinski","year":"2009","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib30","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.clinthera.2007.11.002","article-title":"Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia","volume":"29","author":"Lee","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"Yokote","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2011.07.011_bib32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.clinthera.2008.05.017","volume":"30","author":"Sasaki","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib33","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1253\/circj.CJ-08-1051","article-title":"Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque","volume":"73","author":"Toi","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2011.07.011_bib34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2007.01.040","article-title":"Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function","volume":"125","author":"Sakabe","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0021-9150(01)00712-2","article-title":"A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia","volume":"162","author":"Saito","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2011.07.011_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12325-010-0098-2","article-title":"A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes","volume":"28","author":"Yanagi","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib37","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1185\/03007990903290886","article-title":"Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia","volume":"25","author":"Ose","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2011.07.011_bib38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2005.07.007","article-title":"A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia","volume":"27","author":"Park","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"Hiro","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib40","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0022-2275(20)34443-6","article-title":"Plasma lipoproteins: apolipoprotein structure and function","volume":"25","author":"Mahley","year":"1984","journal-title":"J Lipid Res"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.07.011_bib41","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142010","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2011.07.011_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijcard.2008.11.130","article-title":"High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor","volume":"141","author":"Fukutomi","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0021-9150(01)00765-1","article-title":"Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia","volume":"163","author":"Noji","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2011.07.011_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.clpt.6100396","article-title":"Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study","volume":"83","author":"Kawashiri","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib45","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.07.011_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"115","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2011.07.011_bib47","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1253\/circj.72.538","article-title":"Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia","volume":"72","author":"Mizuguchi","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2011.07.011_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ultrasmedbio.2008.08.011","article-title":"Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy","volume":"35","author":"Ono","year":"2009","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/FJC.0b013e318165dcad","article-title":"Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome","volume":"51","author":"Nakamura","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1253\/circj.70.1624","article-title":"Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design","volume":"70","author":"Miyauchi","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.clinthera.2011.07.011_bib51","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.5551\/jat.5660","article-title":"More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome\u2014sub-analysis of JAPAN-ACS study","volume":"17","author":"Arai","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.clinthera.2011.07.011_bib52","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.07.011_bib53","first-page":"709","article-title":"A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)\u2014Livalo Effectiveness and Safety (LIVES) Study","volume":"36","author":"Kurihara","year":"2008","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2011.07.011_bib54","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2009.12.009","article-title":"Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia","volume":"210","author":"Ose","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2011.07.011_bib55","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1001\/jama.295.23.2752","article-title":"Statin use and incident nuclear cataract","volume":"295","author":"Klein","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2011.07.011_bib56","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.amjcard.2007.04.022","article-title":"Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention","volume":"100","author":"Mood","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2007.04.053","article-title":"Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials)","volume":"100","author":"Murphy","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.07.011_bib58","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2011.07.011_bib59","doi-asserted-by":"crossref","first-page":"539-a","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.07.011_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2010.10.022","article-title":"Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study)","author":"Mizuma","year":"2010","journal-title":"Int J Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811005030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T21:18:39Z","timestamp":1638220719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811005030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0149291811005030"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.07.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}